Novel immune and stromal subtype classification system of lung adenocarcinoma based on tumor microenvironment
Zihang ZengiD, Jiali LiiD, Nannan ZhangiD, Xueping Jiang, Yanping GaoiD, Liexi Xu, Xingyu LiuiD, Jiarui CheniD, Yuke Gao, Linzhi HaniD, Jiangbo ReniD, Yan Qing GongiD, Conghua XieiD
Abstract
BackgroundTumor microenvironment has complex effects on tumorigenesis and metastasis in lung adenocarcinoma (LUAD). However, there is still a lack of comprehensive understanding of the relationship between immune and non-immune stromal characteristics in tumor microenvironment.\n\nPatients and methodsEight cohort of 1681 lung caner patients were included in this study. The immune and non-immune stromal signatures of tumor microenvironment were identified by eigendecomposition and extraction algorithms. We developed a novel immune and stromal scoring system to quantify anti-tumor immune and promote-metastasis stromal activation, namely PMBT (prognostic model based on tumor microenvironment) as an R package. Tumors were classified into 4 subtypes according to PMBT system. Comprehensive analysis was performed in different subtypes.\n\nResultsThe 4 subgroups had different mutation landscape, molecular, cellular characteristics and prognosis, which validated by 7 data sets containing 1175 patients. 19% patients was characterized by highly active anti-tumor reaction with high production of immunoactive mediators, immunocyte, low fibroblasts infiltration, low TGF-{beta}, VEGFA, collagen and glucose catabolic, low immune checkpoint per T cell, tumor mutation burden, and favourable overall survival (all, P < 0.05) named high-immune and low-stromal activation subgroup (HL). Cellular paracrine network showed both high humoral and cellular immune interaction in HL group. The low-immune and high-stromal activation group (19%) had opposite characteristics with HL group. Moreover, the PMBT system showed the value to predict overall survival and immunotherapy responses (all, P < 0.05).\n\nConclusionsDifferent molecular, cellular characteristics, mutation landscape and prognosis were discovered in the 4 subgroups. Our classification, PMBT system provided novel insight for clinical monitoring and treatment in LUAD.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Lung adenocarcinoma WHO histological classes contain distinct immune cell profiles
Anca Năstase, Michael T. Olanipekun, … WO Cookson·medRxiv·Mar 26, 2026
- Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of lung adenocarcinoma
- A prognostic signature for lung adenocarcinoma in people who have never smoked
Wei Zhao, Tongwu Zhang, … Maria Teresa Landi·bioRxiv·Aug 13, 2025
- Immune Infiltration and Survival Analysis in Lung Adenocarcinoma: Identifying Prognostic Cell Types
Madhulika Verma·bioRxiv·May 11, 2024
- Simultaneous immunomodulation and epithelial-to-mesenchymal transition drives lung adenocarcinoma progression
Junbum Kim, Hiranmayi Ravichandran, … Olivier Elemento·bioRxiv·Feb 19, 2025
- High-resolution lung adenocarcinoma expression subtypes identify tumors with dependencies on MET, CDK4, CDK6, and PD-L1